吉非替尼联合简化调强放疗技术治疗非小细胞肺癌临床研究

Clinical Study of Gefitinib Combined with Simplified Intensity Modulated Radiotherapy in Treating Non-Small Cell Lung Cancer

目的探讨吉非替尼联合简化调强放疗技术(s IMRT)治疗非小细胞肺癌的临床效果。方法选取医院2010年1月至2013年12月收治的非小细胞肺癌患者120例,随机分为观察组和对照组,各60例。两组患者均给予s IMRT治疗,观察组患者加用吉非替尼靶向介导治疗。结果观察组有效率为75.00%,明显高于对照组的56.67%(P<0.05);治疗后,观察组患者的表皮生长因子受体(EGFR)、鳞状细胞癌相关抗原(SCC)、癌胚抗原(CEA)及糖类抗原125(CA125)均明显低于对照组(P<0.05);观察组患者的骨髓抑制、消化道不良反应、皮肤不良反应以及肝肾功能损害等发生率与对照组比较无明显差异(P>0.05)。观察组患者的无进展生存期(PFS)和总生存时间(OS)明显长于对照组患者(P<0.05)。结论吉非替尼靶向介导联合s IMRT治疗非小细胞肺癌的临床疗效显著,生存时间长,不良反应少,值得临床推广。

Objective To investigate the clinical effect of Gefitinib combined with simplified intensity modulated radiotherapy（sIMRT） in treating non-small cell lung cancer（NSCLC）. Methods Totally 120 patients with NSCLC from January 2010 to December 2013 in our hospital were randomly divided into the observation group and the control group, 60 cases in each group. The two groups were given sIMRT treatment, on this basis, the observation group added Gefitinib targeted therapy. Results The effective rate in the observation group was 75.00%, which was significantly higher than 56.67% in the control group（P 〈 0. 05）. After treatment, the EGFR, SCC, CEA and CA125 in the observation group were significantly lower than those in the control group（ P 〈 O. 05）. The incidence rate of bone marrow suppression, gastrointestinal adverse reactions, skin adverse reactions and liver and kidney function lesion in the two group had no significance difference（ P 〉 0. 05）. The PFS and OS in the observation group were significantly longer than those in the control group（ P 〈 0.05）. Conclusion Gefitinib combined with sIMRT for treating NSCLC has good effect, and the patients have long survival time and few adverse reactions. It is worthy of clinical promotion.